This observation provides the rationale for HPCAL1 as a surrogate biomarker for HCC treatment with mTOR hyperactivation using mTORi, considering the frequent loss of HPCAL1 in HCC 31. The gene discussed is MTOR; the disease is hepatocellular carcinoma.